The overlap between vascular disease and Alzheimer’s disease – lessons from pathology

Johannes Attems and Kurt A Jellinger

Abstract
Recent epidemiological and clinico-pathological data indicate considerable overlap between cerebrovascular disease (CVD) and Alzheimer’s disease (AD) and suggest additive or synergistic effects of both pathologies on cognitive decline. The most frequent vascular pathologies in the aging brain and in AD are cerebral amyloid angiopathy and small vessel disease. Up to 84% of aged subjects show morphological substrates of CVD in addition to AD pathology. AD brains with minor CVD, similar to pure vascular dementia, show subcortical vascular lesions in about two-thirds, while in mixed type dementia (AD plus vascular dementia), multiple larger infarcts are more frequent. Small infarcts in patients with full-blown AD have no impact on cognitive decline but are overwhelmed by the severity of Alzheimer pathology, while in early stages of AD, cerebrovascular lesions may influence and promote cognitive impairment, lowering the threshold for clinically overt dementia. Further studies are warranted to elucidate the many hitherto unanswered questions regarding the overlap between CVD and AD as well as the impact of both CVD and AD pathologies on the development and progression of dementia.

Keywords: Alzheimer’s disease, Cerebrovascular lesions, Cerebral amyloid angiopathy, Cognitive impairment, Lacunes, Microinfarcts, Small vessel disease, White matter lesions

Introduction
The interaction between cerebrovascular disease (CVD) and Alzheimer’s disease (AD) is a topic of considerable current interest. With age there is an increasing prevalence of coincident AD and CVD that is well recognized. Since 50% to 84% of the brains of persons who die aged 80 to 90+ show appreciable cerebrovascular lesions (CVL) [1], a specific problem is their impact in relation to AD pathology [2-8]. CVD frequently occurs in brains of both non-demented elderly and AD patients. The burden of vascular and AD-type pathologies are leading and independent causes of dementia in the elderly [4,9-15], suggesting additive or synergistic effects of both types of lesions on cognitive impairment [2,3,5,9,16-29].

Epidemiological studies have shown that AD and CVD share common risk factors such as hypertension during midlife, diabetes mellitus, smoking, apolipoprotein E (ApoE) ε4 isoforms, hypercholesterolemia, homocysteinemia, and, in particular, age [16,30-34]. Cardiovascular risk factors, e.g., atrial fibrillation and congestive heart failure, have also been linked to the pathogenesis and progression of AD and are among the most important modifiable risk factors for AD [35-42]. In the Medical Research Council Cognitive Function and Ageing Study, vascular risk factors were not associated with an increased burden of AD pathology at death in old age, whereas cerebral small vessel disease (SVD) and cardiovascular disease were interrelated [43]. According to other studies, non-stroke cardiovascular disease increases the risk of late-life dementia but it is only a risk factor for AD in carriers of the ApoEε4 allele, while the association between cardiovascular disease and dementia is not explained by genetic or early life environmental factors common to both disorders [44]. AD patients with concomitant CVD were reported to be older and more severely demented, but have less severe AD pathology than patients without CVD [23,45].

Review
Coincidence between cerebrovascular disease and Alzheimer’s disease
There is a large body of literature regarding coincidence or overlap of CVD and AD and its correlation with
dementia [1,4,5,9,10,46-48]. Of note, this association was recently found to be stronger in cases with lower neuro-fibrillary tangle pathology (i.e., lower neuritic Braak stages) [5], similar to earlier studies on respective associations with subcortical vascular pathology [6] and general CVD [1]. However, others found an inverse relation between neuritic Braak stage and cerebrovascular pathology in AD [49]. A recent study assessed CVD in 5,715 autopsy cases of the National Alzheimer’s Coordinating Center (NACC) database, and confirmed previous data on the prevalence of CVD in AD and the additive or interactive deleterious effect of both AD and vascular pathologies on cognition [6,9,47,50,51]. However, the role of combined cerebrovascular pathology and AD in dementia is still under discussion and data obtained from epidemiological and clinico-pathological studies regarding their relation are controversial [13,17,22,23,52-55].

AD has been reported to present frequently together with SVD, microvascular injury, and microscopic CVLs [8,16,47,56-60]. SVD-induced ApoE leakage was associated with AD and accumulation of β-amyloid (Aβ) in perivascular astrocytes [61] and transient induction of Aβ deposition [62]. CVD has been shown to induce Aβ deposition, which may by itself cause CVD, in particular micro-vascular degeneration [63]. In addition, aging, per se, has an effect on cerebral arteries in relation to AD since such age related changes may impair the drainage of soluble Aβ out of the brain, which in turn leads to Aβ accumulation in vessel walls and brain parenchyma associated with perturbation of cerebral perfusion and loss of homeostasis of the neuronal environment due to energy failure [64,65]. It was also suggested that more Aβ accumulates with age in brains of vascular dementia (VaD) subjects compared to elderly without CVD [66].

Activity of smooth muscle actin (SMA) was reduced in the brains of patients with late stage AD, while increased arteriolar SMA expression together with frequent Aβ plaques observed in the brains of non-demented subjects suggests that increased SMA expression might represent a physiological response to neurodegeneration that could prevent or delay the onset of clinical dementia in subjects with cerebral AD neuropathology [67]. Vascular disease is thought by many authors to play a major role in the pathogenesis of AD and some even consider AD as being rather a primarily vascular than a neurodegenerative disorder [22,68-74]. Cerebral hyperperfusion-inducing cortical microinfarcts may further aggravate cognitive decline in AD [75]. However, AD pathology alone more frequently accounts for dementia than both macroscopic and microscopic infarcts [15] and, in late stages of AD, concomitant SVLs do not significantly influence the overall state and progression of cognitive decline [45,54,76], the severity and extent of AD pathology overwhelming the rather modest influence of CVD on cognitive impairment [8,77,78]. These data add further evidence for AD pathology (mainly neuro-fibrillary tangles and neuritic plaques) being the main morphological substrate of clinical dementia [51,79,80]. On the other hand, CVD has been associated with worse cognitive performance in AD and neuropathological studies report that CVD lowers the threshold for dementia in subjects with a pathological diagnosis of AD [5,6,8,9,13,17,23,51,53,81-83]. CVD has been suggested to contribute to AD neuropathological changes including selective brain atrophy and accumulation of abnormal proteins such as Aβ [24,35,84,85]. Moreover, AD pathology and subcortical vascular disease may independently affect cortical atrophy [86].

Vascular pathology in aging and Alzheimer’s disease
The types of vascular pathology in the aged human brain include:

- Cerebral amyloid angiopathy (CAA);
- Cerebral atherosclerosis, SVD (in most cases caused by hypertension, i.e., hypertensive vasculopathy), or microvascular degeneration (tortuosity, fibro- and lipohyalinosis);
- Blood–brain barrier (BBB) dysfunction causing white matter lesions (WMLs), microinfarctions, lacunes or lacunar infarcts, and microbleeds [17,87].

All of these pathologies may disrupt the integrity of cerebral vessels and alter brain perfusion leading to neuronal injury and cognitive impairment

CAA results from focal to widespread deposition of Aβ within leptomeningeal and intracortical arteries, arterioles, capillaries, and, rarely, veins causing fibrinoid necrosis, intimal thickening, and microaneurysms. In addition, pericapillary Aβ refers to Aβ depositions in the glia limitans and adjacent neuropil, whereas in capillary CAA Aβ depositions are present in the capillary wall [88]. Sporadic CAA is present in 82% to 98% of AD patients, often associated with ApoE2 and ApoE4 alleles [80], but is also frequently observed in brains of elderly non-demented individuals with an age-related prevalence between 10% and almost 100% [17,89]. The occipital lobe has been reported to be the site most frequently and severely affected by CAA, followed by either frontal, temporal, or parietal lobes [89,90]. CAA may cause lobar intracerebral hemorrhages (ICH) and microbleeds [91]; it is indeed considered a risk factor for non-traumatic ICHs in the elderly and is present in up to 20% of all cases with ICH [92]. However, in a large autopsy cohort, the prevalence of ICH was similar in cases with and without CAA (around 5%) [93,94]. Of note, the majority of cases with CAA-related ICH had hypertension, suggesting that hypertension is an important additional causal factor in CAA-related ICHs [95,96].
The progression of WMLs in subjects with CAA has been associated with incident lobar ICHs [97]. CAA has been suggested to cause cortical microinfarcts [98,99], while others did not confirm such an association [100]. Moderate to severe CAA is considered to be an independent risk factor for cognitive impairment [101].

The clinical diagnosis of CAA is based on the assessment of associated CVLs by magnetic resonance imaging (MRI)/cranial computerized tomography (CCT) and clinical data. Correlations of these criteria with post-mortem neuropathological findings indicate that the diagnosis of probable CAA-related hemorrhage can be made intra vitam with high accuracy [102-105]. In addition to the presence of superficial siderosis, cerebral microbleeds, cortical microinfarcts, and hypointensities in MRI images [106-109], the use of Pittsburgh Compound-B (PiB)-positron emission tomography (PET) is useful in detecting CAA intra vitam [110,111], and a significant decrease of both Aβ-40 and Aβ-42 in cerebrospinal fluid (CSF) may prove useful in the diagnosis of CAA [112,113], while in AD, Aβ-42 but not Aβ-40 are significantly decreased [114].

SVD affects small arteries and arterioles and refers to pathological changes similar to atherosclerosis that are termed small vessel arteriosclerosis/atherosclerosis, lipohyalinosis, or hypertensive arteriopathy [115]. They are common in basal ganglia and in the white matter, while small brainstem arteries usually develop arteriosclerosis only in end stages of SVD and cortical vessels usually do not show signs of SVD [116]. In AD neither Aβ load nor metabolic deficit are dependent on the age of disease onset, but patients with late-onset AD show a significantly higher amount of SVD that influences the association between metabolic deficit and clinical symptoms [117]. SVD is a frequent cause of white matter lesions (WMLs; leukoaraiosis) that are increasingly detected by neuroimaging [118-121]. Enlarged perivascular spaces in the centrum semiovale are MRI markers indicative of CAA (in the overlying cortex), while those in basal ganglia are usually associated with hypertensive arteriopathy [103,104]. Deep cerebral microbleeds (CMB) are mainly linked to subcortical SVD, while both subcortical SVD and CAA interact to increase the risk of lobar CMBs [122,123]. The associated morphological findings include demyelination, axon loss, lacunar infarcts, or enlarged perivascular spaces, most frequently in the frontal, parietal, and occipital white matter [124]. Frontal lobe WMLs have been shown to be associated with neurofibrillary pathology, particularly in the oldest old, while there was no relationship with neocortical Aβ load [125]. Routine histological assessment may underate mild to moderate subcortical vascular lesions, but MRI imaging of fixed post-mortem brains reliably reflects subcortical vascular pathology of the white matter [126,127].

BBB dysfunctions related to SVD leading to a leakage of plasma proteins into enlarged perivascular spaces [61,128] have been described in WMLs and lacunar stroke [129,130]. These observations point towards SVD-related alterations of the pre-capillary BBB segment which are involved in the pathogenesis of WMLs/lacunar infarcts and associated with vascular lesions in addition to AD-related changes [61,116]. Thus, chronic plasma protein leakage into the brain and retention of extracellular fluid due to altered perivascular clearance may contribute to the development of WMLs and/or lacunar infarcts [2,3,87]. Damage to the vasculature may, in turn, impair the BBB integrity as one mechanism by which WMLs may evolve [124]. Mechanisms leading to BBB leakage in aging brains are complex, including oxidative damage and the activation of proteases, matrix metalloproteinases, and cyclooxygenases [131]. Evidence of early increase of BBB changes and their progression with severity of AD-type pathology suggest that BBB dysfunction contributes to damage in the aging brain [132].

Atherosclerosis is a very common vessel disorder in elderly individuals, frequently affecting large- to medium-sized arteries of the entire cardiovascular system (large-vessel disease; LVD). With respect to the cerebrum, it mainly affects the circle of Willis and the carotid arteries, in particular at the level of the carotid bifurcation. It causes narrowing of the arteries’ lumina, thereby reducing the blood flow for the supported region, while rupture of atherosclerotic plaques often leads to thrombosis that results in either occlusion of the vessel or thromboembolisms. Depending on the size of the embolus, it may cause lesions that range from “silent” infarcts or microinfarcts to large cerebral infarcts with overt clinical symptoms. “Silent” lacunar infaracts are frequently detected by MRI or CCT and are not accompanied by any overt clinical symptoms, but double the risk of subsequent stroke and dementia [133]. They have been shown to be associated with atrophy in multiple subcortical structures, ventricular enlargement, and widespread cortical thinning, supporting the assumption of a vascular contribution to neurodegeneration and cognitive impairment [134]. As opposed to large and lacunar infarcts, cortical microinfarcts (CMI) are usually not visible at gross neuropathological examination due to the location of the underlying vessel disorder, multiple cortical CMIs are often associated with CAA, whereas subcortical microinfarcts are mainly linked to SVD or atherosclerosis-related embolism [135]. A systematic review of CMIs reported frequencies of 43% in patients with AD and 24% in non-demented older adults [136], while a 7-Tesla MRI study revealed CMI occurrence in 55% of early AD and 45% of non-demented age-matched controls [137].

Widespread CAA and SVD have been suggested to contribute to neurodegeneration in AD [116]. Moreover,
atherosclerosis in the circle of Willis has been specifically linked to AD [138-140], and the presence of large-vessel CVD was strongly associated with an increased frequency of neuritic plaques, suggesting a common etiology or a reciprocal regulation for atherosclerosis and AD [138,141]. Others, however, saw no direct association between large-vessel cerebral atherosclerosis and AD pathology [142], suggesting that atherosclerosis of the intracranial vessels is an independent and important risk factor for dementia due to potentially reversible pathways unrelated to AD pathology and stroke [143]. The pathophysiology of VaD has been critically reviewed recently [48,144-146].

Topographical distribution of cerebrovascular lesions
In AD brains with minor CVD the majority of CVLs are lacunar infarcts in basal ganglia and white matter, and multiple micro-infarcts. This pattern of topographical distribution of CVLs is very similar to the one seen in “pure” vascular dementia (VaD without AD pathology beyond age-related lesions), where around 68% are lacunar infarcts in subcortical brain areas or strategic infarcts involving the thalamus or hippocampus, whereas only 32.5% were multiple large cortico-subcortical infarcts (Table 1). By contrast, mixed dementia (AD + severe CVD), according to our experience, is more frequently characterized by large or lobar infarcts, and multiple cortico-subcortical lesions (56.6%) than small subcortical lacunar infarcts, micro-infarcts, or strategic infarcts (43.4%, Table 2), suggesting different pathogenic mechanisms between these types of disorders [2,3]. In both pure VaD and AD + minor CVD, microangiopathy (SVD) appears more important than in mixed dementia. The type and average prevalence of CVLs in AD, VaD, mixed dementia, and aged controls is shown in Table 3 [147]. The combination of two or more pathological processes may influence the severity of cognitive deficits, unmasking preclinical dementia due to mild AD lesions, while small CVLs alone, seen in 10% to 50% of aged cognitively unimpaired controls, are not likely to account for a single cause of dementia.

Cerebrovascular and Alzheimer’s disease pathology in demented and non-demented elderly
In a series of 300 autopsy cases of AD, Kalaria and Ballard [148] reported 98% CAA, 100% microvascular degeneration, 31% infarcts of all sizes, and 7% intracerebral hemorrhage, while Olichney [149], in a cohort of 248 autopsy cases of AD, revealed a total of 48% CVLs, with 31% microinfarcts, 12.5% large infarcts, and 13.5% hemorrhages. Comparing 173 autopsy-proven AD cases and 130 age-matched controls, CVL were significantly less frequent in controls (42.4%) as compared to AD (56.4%, P <0.05), and CAA was seen in 97.2% of AD cases, out of which 26% showed severe degrees [150]. In a population-based study of 419 demented persons, with neuropathological data available in 89 (21%), the neuropathological diagnoses were AD (51%), VaD (13%), combined AD + VaD (12%), and others (24%). Criteria for pure VaD using imaging results (Mayo Clinic criteria) showed 75% sensitivity and 81% specificity [151]. In a UK population-based autopsy study on elderly subjects (n =209, 48% demented), neuropathological evidence of CVD was found in 78% and of AD in 70%. The proportion of multiple CVL was higher in the demented group, while only 21% of clinically-demented patients showed “pure” AD pathology at post-mortem, indicating that most patients had mixed disease [152]. In a retrospective series of 730 autopsy cases of AD and 535 age-matched controls, using a four-grade scale for the severity of CVLs, the total prevalence of CVD in AD was significantly higher than in controls (31.6% vs. 23.4%) [153]. In a population based longitudinal study of over-80-year-old brain donors from Cambridge, UK, 53% of subjects presented with clinical dementia. In those cases, neuropathological

| Multiple infarcts (61 = 32.5%) |  |
|--------------------------------|---|
| MCA bilateral                  | 4 |
| MCA left/right                 | 9 |
| MCA bilat. + PCAS/PCAD        | 2/1|
| MCA bilat. + PCA bilat.        | 2 |
| MCAS + PCAS                    | 4 |
| MCAD + PCAD                    | 4 |
| PCA bilateral                  | 3 |
| PCA left/right                 | 5/7|
| ACAS + MCAS                    | 2 |
| ACAD                           | 1 |
| Multiple cortico-subcortico bilateral | 12 |
| Multiple cortico-subcortico left hem. | 2 |

**Table 1 Types and location of cerebrovascular lesions in vascular dementia (total 188)**

- **SAE (subcortical) (108 = 57.4%)**
  - Basal ganglia: 21
  - Basal ganglia + white matter: 31
  - Basal ganglia + thalamus (+white matter): 33
  - Basal ganglia + thalamus (+thalamus): 23

- **SID/strategic infarcts (19 = 10.1%)**
  - Thalamus bilateral: 9
  - Thalamus left: 2
  - Thalamus + hippocampus: 8

*Abbreviations: ACAD, Anterior cerebral artery dexter; ACAS, Anterior cerebral artery sinister; MCA, Middle cerebral artery; MCAD, Middle cerebral artery dexter; MCAS, Middle cerebral artery sinister; PCA, Posterior cerebral artery; PCAD, Posterior cerebral artery dexter; PCAS, Posterior cerebral artery sinister; SAE, Subcortical arteriosclerotic encephalopathy; SID, strategic infarct dementia.*
findings were consistent with AD in 67% and with pure VaD in 4%, while 22% showed mixed pathologies and 1% dementia with Lewy bodies. AD and CVD frequently co-existed in the very old [154]. Among 190 older autopsy cases, 68% had CVLs, vascular score was associated with dementia (OR, 1.6), AD (OR, 1.5), and VaD (OR, 2.0). Leukoencephalopathy, large infarcts, and higher vascular burden were associated with clinical dementia [18]. Analysis of 4,629 cases of the NACC database with autopsy-confirmed neurodegenerative AD classified 79.7% as having CVD [37].

Table 2 Types and location of cerebrovascular lesions in mixed dementia (n = 83)

| Type of Lesion | Number |
|---------------|--------|
| 1) AD + Multiple infarcts (47 = 56.6%) | |
| MCA bilateral | 7 |
| MCA left | 6 |
| MCA right (+ lacunes basal ganglia) | 3/1 |
| MCA + ACA bilat. | 1 |
| MCA + PCA left | 2 |
| MCA + PCA right | 1 |
| MCA + PCA left/right | 3/3 |
| MCA bilat. +PCAD | 1 |
| PCA bilateral | 2 |
| Multiple cort. and subcort. bilateral | 13 |
| Multiple left hemisphere | 4 |
| 2) AD + SAE (subcortical) (33 = 39.8%) | |
| Lacunes basal ganglia | 15 |
| Lacunes basal ganglia + white matter | 8 |
| Lacunes basal ganglia + thalamus | 10 |
| 3) AD + SID/strategic infarcts (3 = 3.6%) | |
| Thalamus bilateral | 2 |
| Thalamus + hippocampus | 1 |

Abbreviations: ACA, Anterior cerebral artery; AD, Alzheimer’s disease; MCA, Middle cerebral artery; PCA, Posterior cerebral artery; SAE, Subcortical arteriosclerotic encephalopathy; SID, strategic infarct dementia.

In a recent study from the Oxford Project to Investigate Memory and Ageing, assessment of the severity of SVD in 161 cases of autopsy-confirmed AD gave no relationship between the SVD score and cognitive scores acquired in the last two years of life nor to blood pressure at entry; further, SVD scores were significantly lower when compared with a cohort of cases with only CVD [8]. Assessment of 175 autopsy cases in the Baltimore Longitudinal Study of Aging cohort found no relationship between the degree of atherosclerosis in the aorta, heart, and intracranial vessels and the degree of AD pathology, while the presence of intracranial atherosclerosis significantly increased the odds of dementia, independent of cerebral infarction [143].

A recent study from the NACC selected 835 subjects that represent the AD continuum. While the cause of mild to moderate dementia remained uncertain in 14% of the patients, plaques and tangles independently predicted cognitive dysfunction, as did severe SVD, CAA, and hippocampal sclerosis. Thus, concomitant CVD strongly correlated with cognitive impairment in this sample selected to represent the AD pathology continuum, confirming the uncertainty of AD clinico-pathological correlations based only on neurofibrillary tangles and Aβ plaques [155]. Assessment of 856 participants of two longitudinal clinico-pathological studies (Rush Memory and Aging Project and Religious Orders Study, autopsy rate 80%, mean age at death 88.2 ± 6.5 years) showed that global AD pathology, Aβ plaques, neurofibrillary tangles, macroscopic infarcts, and neocortical Lewy bodies were associated with faster rates of decline and explained 22%, 6%, 34%, 2%, and 8% of the variation in decline, respectively. However, much of the variation in cognitive decline remains unexplained, suggesting that other important determinants of cognitive decline remain to be identified [156].

In a consecutive autopsy series of 494 cases (257 autopsy-proven AD, mean age 83.1 ± 8.4 years and 237 age-matched non-demented controls), 42.7% of the AD

Table 3 Common lesions in AD, VaD, MIX, and aged controls (from [130])

| Pathological feature | AD [%] | VaD [%] | MIX [%] | Aged controls [%] |
|---------------------|--------|---------|---------|------------------|
| Cerebral amyloid angiopathy | 98 | 30 | ~90 | 23-45 |
| Small vessel disease/MVD | ~50 | >50 | >50 | ~20 |
| Total infarctions | 10-20 | 100 | 30-40 | >10 |
| Microinfarcts/lacunes | 30-46 | 70 | 60-70 | 17-21 |
| Intracerebral hemorrhage | 10-15 | 15 | 10 | 1-2 |
| White matter pathology | 40 | 80 | 70-80 | <20 |
| Loss of cholinergic markers | 75 | 40 | ~70 | |
| CVD/atherosclerosis | 45-60 | 60 | ~60 | 30-53 |

Abbreviations: AD, Alzheimer’s disease; CVD, Cerebrovascular disease; MIX, mixed type dementia (AD plus vascular dementia); MVD, Microvascular disease; VaD, Vascular dementia.
Many studies emphasized multiple confounding pathologies in non-demented elderly subjects, in particular CVLs, e.g., small or large cerebral infarcts, lacunes, and WMLs, in up to 10% [10,165-167]. Among 418 non-demented participants of the Religious Order Study (mean age 88.5 ± 5.3 years), 35% showed macroscopic brain infarcts and 14.8% arteriosclerosis, while only 37.5% were free of any CVD [168]. Various degrees of CAA have been found in up to 75% of cognitively normal seniors [167]. Among 100 non-demented elderly, mild, moderate, and severe intracranial atherosclerosis was present in 31%, 17%, and 6% of subjects, respectively. A lacunar state in basal ganglia and/or white matter was observed in 73%, hippocampal sclerosis in 3%, and mixed cerebral pathologies in 6%, whereas only 9% were free of CVLs [169]. A recent cross-sectional study in a community-based sample of 72 cognitively normal older individuals (mean age 74.9 ± 5.7 years) confirmed that a substantial number harbor neurodegeneration without Aβ burden, but association of neurodegenerative lesions with CVD can emerge through non-Aβ pathways within regions most affected by AD [170].

Pathogenic factors

Microvascular changes in the aged brain and in AD induce impairment of cerebral perfusion, in particular decrease of regional blood flow, reduction of glucose transport and utilization, loss of vascular innervation with special impact on the cholinergic and transmitter deficits in AD [171], impairment of neurovascular regulation, ultrastructural changes in capillaries and basement membranes due to deposition of Aβ, with breakdown of the BBB and impairment of amyloid clearance. The pathogenic chain of these and other deleterious effects, in a vicious circle, finally produces either structural cerebral disintegration (lacunes, infarcts, WMLs) with compromised neuronal metabolism, mitochondrial deficiency, oxidative stress, protein degradation, failure promoting cytoskeletal lesions with deposition of Aβ, and formation of neuritic lesions (e.g., neurofibrillary tangles). These factors induce brain atrophy with cognitive and memory impairment (Figure 1) [147], although the complex cascade of these and other noxious factors needs further elucidation.

The role of vascular pathology as a factor contributing to AD is a topic of current interest, with a wide overlap between both disorders. Both hypertension and CAA are associated with an increased prevalence of CVLs [157], and both human and experimental studies in transgenic mice overexpressing amyloid precursor protein suggest that cerebrovascular effects of Aβ render the aged brain more vulnerable to ischemic injury [172]. Both atherosclerosis and CAA cause changes in microvasculature auto-regulation and thus may lead to myelin
loss, frequently seen in aged and diseased brains, suggesting shared risk factors for all pathological changes seen in AD and CVD. WMLs may be caused by both CVD (hypoperfusion) and AD (retrograde degeneration), they progress with age, and they are a considerable risk factor for cognitive impairment [120,173,174]. They impair frontal functions regardless of their location [175,176] and increase the risk of dementia, particularly in patients with lacunar infarcts [177,178], causing functional network disruption in cognitively-impaired individuals compared with age-matched healthy elderly controls [179,180]. Although WMLs and lacunes may be independently associated with cognitive dysfunction [181,182], WMLs in AD are significantly correlated to cortical and medial temporal lobe atrophy [181-183], and, thus, are assumed to contribute to cognitive decline [184]. Together with cortical microinfarcts, WMLs may contribute to the progression of cognitive impairment, but do not necessarily interact with AD pathology to increase the likelihood of dementia beyond their additive effect [20]. Further, the neuropathological evaluation of focal and white matter gliosis may have no clinical validity [185].

Conclusions
CVD has been suggested to be an important cause of cognitive impairment in the elderly, both by itself or as a catalyst for the conversion of low-grade AD to overt dementia [186]. Hence, the combination of both AD and vascular or other pathological processes, as seen in many elderly persons, may coexist in the earlier stages of cognitive decline and may influence its progression and severity, thus representing a major diagnostic challenge not only for clinicians but also for neuropathologists. Despite multiple attempts, there is still a lack of consensus regarding the optimal means of incorporating vascular disease into clinical and neuropathological classification schemes for dementias. Therefore, an integrating rather than a strictly taxonomic approach (instead of discriminating AD, VaD, and other diseases) to elucidate specific pathophysiological mechanisms that contribute to dementia phenotypes and neuropathological causes has been proposed [37].

To improve the diagnostic specificity on the interaction between AD and CVD pathologies, a multivariable and multimodality algorithm is required. While structural MRI results have limited security and specificity, a number of in vivo studies using functional MRI [187] and amyloid and tau PET (e.g., PiB, florbetabin, flutemazole, etc.) [188-190] will enable the identification of AD and CVD patients in clinical and research settings. However, recent evidence comparing PiB-PET with post-mortem or biopsy results raised doubts about this method as representative of Aβ loads in the living brain [191,192] and PiB-positivity was observed in 55% of non-demented subjects over 80 [193]. The recent development of in vivo amyloid imaging enables further pathological breakdown of SVD into pure forms and mixed dementia based on the absence or presence of amyloid pathology in the brain [194]. Modern CSF biomarkers may support a direct relationship between SVD and AD pathology [195], although in the Alzheimer Disease Neuroimaging Initiative that is focused on AD, no interactions were noted between vascular risk factors and AD biomarkers [26]. Therefore, differentiation of mixed
AD/CVD with CSF biomarkers may be difficult. Converging evidence from autopsy, amyloid PET, functional MRI, and CSF biomarker studies indicate that AD and CVD exert additive rather than interactive adverse effects on cognitive health, but interaction between various vascular factors and amyloidosis/tauopathy still remain unresolved. Further studies to more accurately elucidate the impact of vascular disease and AD-related brain pathology are an important challenge for neuroscience as such studies could serve as a basis for the development of efficient therapies against age associated dementias.

Abbreviations
AJ: α-amyloid; AD: Alzheimer’s disease; ApoE: Apolipoprotein E; BBB: Blood–brain barrier; CAA: Cranial amyloid angiopathy; CCT: Cranial computerized tomography; CMb: Cerebral microbleed; CMl: Cortical microinfarcts; CSF: Cerebrospinal fluid; CVD: cerebrovascular disease; CVL: Cerebrovascular lesions; IC: Intracerebral hemorrhages; LVD: Large-vessel disease; MRI: Magnetic resonance imaging; NACC: National Alzheimer’s Coordinating Center; PiB: Pittsburgh compound-B; PET: Positron emission tomography; SMA: Smooth muscle actin; SVD: Small vessel disease; VaD: Vascular dementia; WML: White matter lesions.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
KAI drafted the manuscript and JA critically revised the manuscript. Both authors read and approved the final manuscript.

Acknowledgements
JA is funded by the Dunhill Medical Trust (R173/1110) and by the National Institute for Health Research (NIHR) Biomedical Research Centre for Ageing and Age-related disease and the Biomedical Research Unit for Lewy Body Dementia based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University (RCH/ML/0712). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Tissue for original work by JA cited in this review was obtained by the Newcastle Brain Tissue Resource, which is funded in part by a grant from the UK Medical Research Council (G0400074) and by Brains for Dementia Research, a joint venture between Alzheimer’s Society and Alzheimer’s Research UK.

Author details
1Institute of Neuroscience, Newcastle University, Campus for Ageing and Vitality, NE4 5PL. Newcastle upon Tyne, UK. 2Institute of Clinical Neurobiography, Medical University Vienna, Kenngasse 18, 1070 Vienna, Austria.

Received: 1 July 2014 Accepted: 7 October 2014

Published online: 11 November 2014

References
1. Petrovitch H, Ross GW, Steinhorne SC, Abbott RD, Markesbery W, Davis DG, Nelson J, Hardman J, Masaki KH, Vogt MR, Launer LJ, White LR. AD lesions and infarcts in demented and no-demented Japanese-American men. Ann Neurol 2005, 57:98–103.
2. Jellinger KA: The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 2007, 113:349–388.
3. Jellinger KA: The enigma of mixed dementia. Alzheimers Dement 2007, 3:40–53.
4. Schneider JA, Anvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007, 69:2197–2204.
5. Toledo JB, Arnold SE, Raffle K, Bretschneider J, Xie SX, Grossman M, Monsell SE, Kukul WA, Trojanowski JQ: Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Center. Brain 2013, 136:2697–2706.
6. Chui HC, Zawor C, Mark WJ, Ellis WG, Zheng L, Jagust WJ, Mungas D, Reed BR, Kramer JH, Decarli CC, Weiner MW, Vinters HV. Cognitive impact of subcortical vascular and Alzheimer’s disease pathology. Ann Neurol 2006, 60:677–687.
7. Giannakopoulos P, Gold G, Kavari E, von Ganten A, Imhof A, Bouras C, Hof PR: Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol 2007, 113:11–12.
8. Eser MM, Joachim C, Sloan C, Christie S, Agacinski G, Bridges LR, Wilcock GK, Smith AD: Cerebral subcortical small vessel disease in subjects with pathologically confirmed Alzheimer disease: a clinicopathologic study in the Oxford Project to Investigate Memory and Ageing (OPTIMA). Alzheimer Dis Assoc Disord 2014, 28:35–30.
9. Snowden DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. Neurology 1999, 53:817–820.
10. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 2009, 18:691–701.
11. Schneider JA, Wilson RS, Cochran EJ, Baniasili N, Arnold SE, Evans DA, Bennett DA: Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003, 60:1082–1088.
12. Jellinger KA: Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis 2010, 7:12–115.
13. Eser MM, Nagy Z, Smith MZ, Barterton L, Smith AD: Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 1999, 354:919–920.
14. Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schelldenbg GD, craft S, Leverenz JB, Montine TJ: Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007, 62:406–413.
15. Troncoso J, Zonderman AB, Resnick SM, Cian B, Pietrnikova O, O’Brien R: Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 2008, 64:168–176.
16. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Selife FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:2672–2713.
17. Jellinger KA: Alzheimer disease and cerebrovascular disease: a new concept. J Neurol Neurosurg Psychiatry 2002, 109:813–836.
18. Strozyk D, Dickson DW, Lipton RB, Katz M, Derby CA, Lee S, Wang C, Verghese J: Contribution of vascular pathology to the clinical expression of dementia. Neurobiol Aging 2010, 31:1710–1720.
19. Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol Aging 2008, 29:1587–1590.
20. Costanza A, Xekardaki A, Kavari E, Gold G, Bouras C, Giannakopoulos P: Microvascular burden and Alzheimer-type lesions across the age spectrum. J Alzheimers Dis 2012, 32:643–652.
21. Eser MM, Chance SA: Cognitive reserve, cortical plasticity and resistance to Alzheimer’s disease. Alzheimer’s Res Ther 2012, 4:7.
22. Kalaria RN: The role of cerebral ischemia in Alzheimer’s disease. Neurobiol Aging 2000, 21:321–330.
23. Zeki S, Dwykaerts C, Moulas R, Belmin J, Geoffr F, Hermann F, Haus JD: Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol (Berl) 2002, 103:841–847.
24. Kalaria RN: Risk factors and neurodegenerative mechanisms in stroke related dementia. Panminerva Med 2012, 54:139–148.
25. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA: Relation of neuropathology to cognition in persons without cognitive impairment. Ann Neurol 2012, 72:699–699.
26. Lo RY, Jagust WJ: Vascular burden and Alzheimer disease pathologic progression. Neurology 2012, 79:1349–1355.
27. O’Brien TJ, Wadley V, Nicholas AP, Stover NP, Watts R, Griffith HR: The contribution of executive control on verbal-learning impairment in patients with Parkinson’s disease with dementia and Alzheimer’s disease. Arch Clin Neuropsychol 2009, 24:237–244.
115. Pantoni L: Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010, 9:689–701.

116. Thal DR, Ghebremedhin E, Orantes M, Westler OD: Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/phyloinvasion with cognitive decline. J Neuropathol Exp Neurol 2003, 62:1387–1401.

117. Ortner M, Kurz A, Alexopoulos P, Auer F, Diehl-Schmid I, Drezga A, Forster S, Forstl H, Penczek R, Sorg C, Youssefi BH, Grimmer T: Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer’s disease, Biol Psychiatry. In press.

118. Doubal FN, MacLullich AM, Ferguson JK, Dennis MS, Wardlaw JM: Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 2010, 41:540–545.

119. Duering M, Csanadi E, Gesierich B, Jouvent E, Herde D, Seiler S, Belaraoussii B, Ropele S, Schmidt R, Chabrat B, Dihgians M: Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain 2013, 136:2717–2726.

120. Schmidt R, Schmidt H, Haybäck J, Loitfeller M, Weis S, Cavaioni M, Seiler S, Erntinger C, Ropele S, Erkunjntti T, Panton I, Schelten P, Fazekas F, Jellinger K: Heterogeneity in age-related white matter changes. Acta Neuropathol 2011, 122:171–185.

121. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayn R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C, Brelter M, Chabrat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox NC, Greenberg S, Harchinski V, Killmann M, Vok M, Oostenbrugge R, Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, et al: Neuroimaging standards for research into small vessel disease and its contribution to age and neurodegeneration. Lancet Neurol 2013, 12:822–838.

122. Cordonnier C, van der Flier WM: Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011, 134:335–344.

123. Park JH, Seo SW, Kim C, Kim GH, Noh HJ, Kim ST, Kwak KC, Yoon U, Lee JM, Young VG, Halliday GM, Kril JJ: Vermeer SE, Longstreth WT Jr, Koudstaal PJ: Silent brain infarcts: a systematic review. Lancet Neurol 2007, 6:611–619.

124. Thong YH, Hill S, Wang Y, Soon HW, Dong Y, Collinson SL, Anh TT, Ilram MK, Wong TY, Venketasubramanian N, Chen C, Qua A: Association of silent lacunar infarct with brain atrophy and cognitive impairment. J Neurol Neurosurg Psychiatry 2013, 84:1219–1225.

125. Thal DR, Griffin WS, de Vos RA, Ghebremedhin E: Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathol 2008, 115:599–602.

126. Bundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ: Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab 2012, 32:425–436.

127. van Veluw SJ, Heringa SM, Kuif HJ, Koek HL, Luijten PR, Biessels GJ: Cerebral cortical microinfarcts at 7 Tesla MRI in patients with early Alzheimer’s disease. J Alzheimers Dis 2013, 39:163–167.

128. Jellinger K, Attems J: Alzheimer pathology in neurodegenerative dementia. Brain 2012, 135:3749–3756.

129. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, C, Connor DJ, Sabbagh M, Walker DG, Roher AE: Circle of Willis arteriosclerosis association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 2007, 113:13–21.

130. Pantoni L, Kurz A, Alexopoulos P, Auer F, Diehl-Schmid J, Drzezga A, Forster S, Forstl H, Penczek R, Sorg C, Youssefi BH, Grimmer T: Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer’s disease, Biol Psychiatry. In press.

131. Roher AE, Tyas SL, Mauroof CL, Daugs ID, Koljoh TA, Emmering MR, Garami Z, Belchavek M, Sabbagh MN, Sue LI, Beach TG: Intracranial arteriosclerosis as a contributing factor to Alzheimer’s disease dementia. Alzheimers Dement 2011, 7:436–440.

132. Jellinger K, Attems J: Pathobiology of cerebral small vessel disease. Neurology 2005, 64:494–500.

133. Jellinger KA: Challenges in the neuropathological diagnosis of dementias. Neurobiol Aging 2009, 30:99–98.

134. Jellinger KA, Attems J: Pathogenesis and treatment of vascular cognitive impairment. Neurodeg Management 2014. In press.

135. Jellinger KA, Attems J: Neuropathological evaluation of mixed dementia. J Neurol Sci 2007, 257:80–87.

136. Jellinger KA, Attems J: Neuropathological evaluation of mixed dementia. J Neurol Sci 2007, 257:80–87.

137. Jellinger KA, Attems J: Incidence of cerebrovascular lesions in Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999, 13:S115–S123.

138. Gilchrist JM, Ellis RJ, Katsman R, Sabbagh MN, Hanssen L: Types of cerebrovascular lesions associated with severe cerebral amyloid angiopathy in Alzheimer’s disease. Ann N Y Acad Sci 1997, 826:493–497.

139. Jellinger KA: Attems J: Incidence of cerebrovascular lesions in Alzheimer disease: a postmortem study. Acta Neuropathol 2003, 105:14–17.

140. Kukull WA, Black SE, Brayne C, Breteler MM, Koudstaal PJ: Stroke and dementia in a population-based autopsy study. Arch Neurol 2003, 60:569–575.

141. Fernando MS, Ince PG: Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 2004, 226:13–17.

142. Jellinger KA, Mitter-Fersot E: The impact of cerebrovascular lesions in Alzheimer disease. A comparative autopsy study. J Neurol, 2003, 250:1005–1055.

143. Kukull WA, Black SE, Brayne C, Roher AE, Roeloffzen CA: Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the national Alzheimer Coordinating Center. Neurology 2001, 56:660–666.

144. Altschuler JS, Iwatsubo T, Selkoe DJ, Lippa AS, Jicha GA, Vinters HV, Rogaev EI, Smith MA, Borchelt DR, Multhaup G, Selkoe DJ, Cohen JA, Birnbaum D, Clark J, Lipton L, Chabriat H, Dichgans M: Ex vivo imaging of amyloid and perivascular spaces on MRI are a feature of cerebral small vessel disease. Stroke 2011, 42:2571–2577.
